Skip to search formSkip to main contentSkip to account menu

AZD8055

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

mTOR Kinase Inhibitor AZD8055

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
2017
2017
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is frequently activated in cancers and can be counteracted with the… 
2016
2016
Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells.
2016
2016
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify… 
2016
2016
A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis.
Individuals are at risk of exposure to acute ionizing radiation (IR) from a nuclear accident or terrorism, but we lack effective… 
2016
2016
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
The mechanistic target of rapamycin (mTOR) is a rational target for cancer treatment. While the mTORC1-selective rapalogs have… 
2015
2015
Screening of mammalian target of rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid chromatography-tandem mass spectrometry.
2015
2015
Leukemia inhibitory factor increases glucose uptake in mouse skeletal muscle.
Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty… 
2014
2014
Adenosine Triphosphate‐Competitive mTOR Inhibitors: A New Class of Immunosuppressive Agents That Inhibit Allograft Rejection
The mechanistic/mammalian target of rapamycin (mTOR) is inhibited clinically to suppress T cell function and prevent allograft… 
Review
2011
Review
2011
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
AZD8055 is a small-molecule inhibitor of mTOR (mammalian target of rapamycin) kinase activity. The present review highlights… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)